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Abstract
Time-course model-based network meta-analysis (MBNMA) has been pro-
posed as a framework to combine treatment comparisons from a network of
randomized controlled trials reporting outcomes at multiple time-points. This
can explain heterogeneity/inconsistency that arises by pooling studies with dif-
ferent follow-up times and allow inclusion of studies from earlier in drug
development. The aim of this study is to explore using simulation: (a) how
MBNMA model parameters are affected by the quantity/location of observed
time-points across studies/comparisons, (b) how reliably an appropriate
MBNMA model can be identified, (c) the robustness of model estimates and
predictions under different dataset characteristics. Our results indicate that
model parameters for a given treatment comparison are estimated with low
mean bias even when no direct evidence was available, provided there was suf-
ficient indirect evidence to estimate the time-course. A staged model selection
strategy that selects time-course function, then heterogeneity, then covariance
structure, identified the true model most reliably and efficiently. Predictions
and parameter estimates from selected models had low mean bias even in the
presence of high heterogeneity/correlation between time-points. However, fail-
ure to properly account for heterogeneity/correlation could lead to high error
in precision of the estimates. Time-course MBNMA provides a statistically
robust framework for synthesizing direct and indirect evidence to estimate rel-
ative effects and predicted mean responses whilst accounting for time-course
and incorporating correlation and heterogeneity. This supports the use of
MBNMA in evidence synthesis, particularly when additional studies are avail-
able with follow-up times that would otherwise prohibit their inclusion by con-
ventional meta-analysis.
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1 | BACKGROUND
Network meta-analysis (NMA)1,2 is commonly used to
synthesize evidence from multiple studies on multiple
treatments simultaneously. NMA pools evidence from all
studies that form a connected network of treatment com-
parisons, so that inference on relative treatment effects is
strengthened by combining direct head-to-head evidence
with indirect evidence from the rest of the network.
NMA can increase precision of estimates compared with
standard pairwise meta-analysis, but it relies on the con-
sistency assumption that there are no differences
between direct and indirect treatment effects.3,4 One rea-
son the consistency assumption may not hold is if differ-
ent studies report results at different follow-up times, and
this is not accounted for in the analysis. Furthermore, the
relationship between treatment efficacy and time may be
of interest in itself, for example the characterization of a
treatment's onset and offset of action.
A number of different methods for incorporating lon-
gitudinal data into NMA have been proposed. Riley et al5
and Ishak et al6 used multivariate methods to incorporate
multiple follow-up times, whereas Dakin et al7 presents a
hierarchical model. Both approaches can capture differ-
ences between treatment effects at different follow-up
times, but do not deliver an estimated time-course for rel-
ative treatment efficacy. To obtain an estimated time-
course relationship requires a parametric model. Frac-
tional polynomials8 and exponential time-course func-
tions9 have been proposed, and more recently, model-
based network meta-analysis (MBNMA), a general frame-
work for NMA that incorporates parametric models of
time-course relationships has been developed.10
By pooling relative effects within studies, time-course
MBNMA preserves randomization and allows for testing
of consistency between direct and indirect evidence in the
network, whilst making use of all the available evidence at
different time points. The benefit of this approach com-
pared with NMA is that it allows inclusion of studies with
a range of follow-up times, and therefore provides the pos-
sibility of including clinical trials from earlier in clinical
development which may contribute valuable information
on treatment efficacy. The method can be used with any
parametric time-course relationship, (including exponen-
tial, Emax, and fractional polynomials), although because
MBNMA is typically based on aggregate data only,
identifiability may be an issue for models using time-
course functions with two or more parameters.10
MBNMA was developed using a dataset of studies
investigating pain relief in osteoarthritis10 which con-
sisted of 30 RCTs comparing 29 treatments for pain relief,
measured on the Western Ontario and McMaster Univer-
sities Arthritis Index (WOMAC) scale11 and recorded at
multiple time points up to a maximum of 24 weeks (Fig-
ure S1). Following a model selection strategy, the time-
course that most closely fitted the data was an Emax func-
tion. By modeling the time-course in this dataset using
MBNMA, it was possible to include all studies and all
treatments in the dataset, despite studies reporting out-
comes at a range of different follow-up times. This
explained significant heterogeneity and inconsistency
that was present when using a single, latest follow-up
time from each study, an improper approach that is
sometimes used in meta-analysis.
However, this analysis raised several questions as to
the statistical properties of the method. Model fit statis-
tics were used to compare between different models, yet
we were unclear of the extent to which measures such as
the deviance information criterion (DIC) could be mean-
ingfully used. MBNMA allows a range of different time-
course models to be fitted, and results may be sensitive to
misspecification of the underlying time-course function.
What is already known?
MBNMA is a new technique for evidence
synthesis that allows incorporation of parametric
time-course into NMA, which allows inclusion of
studies with different follow-up times in a man-
ner that can explain heterogeneity/inconsistency.
What is new?
This study highlights the robustness of the time-
course MBNMA framework and the selection
strategy that can be used to identify an appropri-
ate model. In particular, it identifies under which
conditions results from MBNMA models are
likely to be of value, and in which there may be
limitations.
Potential impact for RSM readers
outside the authors' field
By demonstrating that time-course can be
included in NMA in a statistically robust manner,
we hope that this will allow the inclusion of trials
from drug development into reimbursement
agency decision-making. Doing so can help
bridge the gap in evidence synthesis techniques
that currently exist between pharmacometrics
and Health Technology Appraisal.
2 PEDDER ET AL.
Furthermore, results at multiple follow-up times from
the same study will be correlated, with different choices
for how this can be modeled. It is therefore important to
assess how sensitive model results are to misspecification
of the time-course function and correlation structure, and
how best to select between different models.
Comparisons within the network also contained vary-
ing numbers of observations with which to inform the
time-course. When estimating time-course parameters for
a given non-linear function (eg, exponential, Emax), we
expect that the number and location of observed follow-
up times across studies and comparisons in the network
are likely to be a critical factor in determining
identifiability and the precision with which parameters
can be estimated. In practice, as in the pain relief in oste-
oarthritis example, study follow-up times are likely to be
picked to fit with a reasonable visit schedule for patients,
along with the main landmark time point(s) of interest.
Therefore, it is necessary to understand what impact the
presence of different follow-up times will have in the esti-
mation of the parameters in the network.
In this paper, we aim to investigate the performance
of MBNMA time-course models applied to datasets gen-
erated with varying characteristics. We divide this paper
into two related simulation studies which aim to answer:
1. How are MBNMA model parameters affected by the
quantity and location of observed time points across
studies and comparisons in the network?
2. How reliably is an appropriate time-course MBNMA
model identified?
3. How robust are model estimates and predictions
under different dataset characteristics?
The results from these studies can help identify in
which circumstances these models can be expected to
perform well, and in which they might perform poorly,
allowing the robustness of conclusions drawn from
time-course MBNMA to be considered in light of the
number/location of observations reported in the data,
the assumptions made within the modeling process,
and the purpose for which the model will be used (ie,
whether time-course parameters or predicted means
are of interest). We begin by describing the time-
course MBNMA model. We then describe the methods
used for the two simulation studies, before presenting
results and conclusions.
2 | TIME-COURSE MODEL-BASED
NETWORK META-ANALYSIS
We briefly explain methods for time-course MBNMA. A
more detailed explanation can be found in Pedder et al.10
2.1 | Likelihood
We assume we have a summary outcome, such as mean
outcome or log-odds of response, yi, k, m, together with
standard errors, sei, k, m, reported for each study i, arm
k = 1, …, Ki, and at time point m = 1, …, Mi, where study
i has Ki arms and reports outcomes at Mi time points. We
let si, m be the actual time at which the mth time point in
study i was observed. The treatment given in study i, arm
k, is indicated by ti, k.
We assume the summary outcome has been trans-
formed onto a scale where a Normal likelihood is
appropriate:
yi,k,m N θi,k,m,sei,k,mð Þ
in which θi,k,m is the modeled outcome (eg, predicted
mean on the relevant scale) at time point m in arm k of
study i.
However, when we have repeated measures from the
same individuals within each study, the observations
may be correlated, which can be captured with a multi-
variate Normal likelihood:
yi,k MVN θi,k,Σi,kð Þ
where yi, k is a vector of the observed summary measures
across the time points measured in that trial, θi, k is a vector
of modeled outcomes, and Σi,k is an Mi × Mi covariance
matrix:
Σi,k =
se2i,k,1 ρi,k,1,2sei,k,1sei,k,2    ρi,k,1,Misei,k,1sei,k,Mi
ρi,k,1,2sei,k,1sei,k,2 se
2
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where ρi,k,m1,m2 is the within-study correlation between sum-
mary measures at time pointsm1 andm2 for study i arm k.
Common correlation parameters across arms and stud-
ies are typically assumed in order to improve identifiability.
Furthermore, some constraints on the covariance structure
are required, such as assuming a compound symmetry
(CS) or autoregressive (AR1) covariance structure.10
2.2 | Time-course model
We put the time-course model on the aggregate-level means:
θi,k,m = f si,m,λi,kð Þ
where f defines a functional relationship over time si,m, and
λi, k = (λ0,i,k,λ1,i,k,λ2,i,k, …) are a set of parameters that
describe the relationship in mean outcomes over time.10 In
all time-course models there will be a “nuisance parameter”
λ0,i,k which represents the “intercept” at time s = 0. We put
our modeling assumptions on the remaining parameters, λ1,
i,k, λ2,i,k, …, leaving the λ0,i,k unconstrained (achieved in a
Bayesian analysis by giving independent vague prior distri-
butions to the λ0,i,k parameters).
For example, for a two-parameter Emax time-course
function there are two time-course parameters, and a
baseline response (λ0,i,k = E0,i,k - the mean response at
baseline in arm k of study i):
f si,m,λi,kð Þ=E0,i,k + Emax,i,k × si,mET50,i,k + si,m ð1Þ
Emax, i, k (equivalent to λ1,i,k) is the maximum mean
difference from baseline in arm k of study i and ET50,i,k
(equivalent to λ2,i,k) is the time at which 50% of the maxi-
mal effect has been reached in arm k of study i.
2.3 | Network meta-analysis
The network meta-analysis (NMA) model describes the
impact of treatments on one or more of the parameters of
the time-course model, λ1,i,k, λ2,i,k, …. If the NMA model
is given for a single time-model parameter, λ1,i,k, we have:
g λ1,i,kð Þ= μ1,i + δ1,i,k
for a given link function g which transforms the outcome
to a scale where relative treatment effects may be
expected to be additive. μ1,i is the time-course model
parameter (on the transformed scale) for arm 1 of study i,
and δ1,i,k the study-specific relative effect for the treat-
ment used in arm k relative to arm 1 of study i.
For a two-parameter time-course function such as the
Emax model we put the NMA model for the Emax parame-
ter, λ1,i,k, on the natural scale and the NMA model for the
ET50 parameter, λ2,i,k, on the log-scale to ensure that it
can only take positive values:
λ1,i,k = μ1,i + δ1,i,k
log λ2,i,kð Þ= μ2,i + δ2,i,k
RCTs provide comparative evidence between treat-
ments and so our focus is on the estimation of relative
effects between treatments. In these circumstances μ1, i
and μ2, i are handled as nuisance parameters and given
independent vague prior distributions in a Bayesian anal-
ysis to allow them to be unconstrained.1,2
Treatment effects on each time-course parameter can be
either assumed “common” (often called “fixed” in meta-anal-
ysis literature) or “random” (sometimes referred to as
“exchangeable”) across studies. For the random effects model,
study-specific treatment effects are assumed to be normally
distributed around a mean treatment effect that adheres to
the consistency relationships, with common between-studies
variance τ2 across treatment comparison. For a two-parame-
ter time-course function with random effects on both time-
course parameters this would be as follows:
δ1,i,k N d1,ti,k −d1,ti,1 ,τ21
 
δ2,i,k N d2,ti,k −d2,ti,1 ,τ22
  ð2Þ
The consistency relationships reflect the comparison
made between the treatment ti,k used on arm k and the
treatment ti,1 used on arm 1 of each study. The common
effect model for each time-course parameter is obtained
by setting τ21 = 0 or τ
2
2 = 0 respectively.
The model estimates “basic parameters” d1,1,k and d2,1,k,
the pooled mean relative effect for treatment k relative to
treatment 1 (the reference treatment for the NMA) for each
time-course parameter. All other relative effects for treat-
ment k relative to treatment c, d1,c,k and d2,c,k, can then be




2.4 | Simulation study methods
Simulation scenarios were motivated by a time-course
MBNMA used to analyze a dataset of pain relief in osteo-
arthritis.10 We conducted two separate simulation studies
to evaluate our research questions:
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1. Simulation Study I
i. How are MBNMA model parameters affected by
the quantity and location of observed time points
across studies and comparisons in the network?
2. Simulation Study II
i. How reliably is an appropriate time-course
MBNMA model identified and how robust are
model estimates and predictions when different
model selection strategies are used, under different:
a. Covariance structures
b. Levels of correlation between observations
c. Levels of heterogeneity
In Study I we explore the data requirements to fit
an Emax MBNMA model to studies forming a closed
network of three treatments by varying quantity and
location of time points within studies. The results of
this were then used to define scenarios with different
time points in Study II with which to explore the per-
formance of different model selection strategies on data
with different covariance structures and different
degrees of correlation between observations and hetero-
geneity (Figure 1).
Simulation protocols for each study were developed
following the Aims, Data-generating mechanisms,
Methods, Estimands, Performance measures (ADMEP)
approach.13 In this section we first describe the data-gen-
erating mechanisms used for all simulations, before
describing aspects specific to the two simulation studies.
We then describe the different models fitted in the two
simulation studies, the performance measures that were
computed, and the implementation.
FIGURE 1 Illustrates how datasets were generated with observations present at different time points. Within each matrix, each row
represents a different treatment comparison (one for each of the three in the network), and each column represents a different time point
(calculated as ET, the time at which a percentage of the maximum response is achieved). Within a particular time point pattern, shaded cells
represent observations that are present and white cells represent observations that are not present. If an entire row is white, this indicates
studies have been removed for that treatment comparison. Time point removal patterns have been numbered to aid reference in the paper.
In patterns 2 to 10, time points are removed from only a single treatment comparison, whilst in patterns 11-18 time points are
simultaneously removed from two treatment comparisons. The arrow between the two studies indicates that results from Study I helped
inform the design of Study II, and led to the selection of patterns 1, 5, 9 and 10 for further comparison when investigating the impact of
different degrees of heterogeneity and correlation between time points [Colour figure can be viewed at wileyonlinelibrary.com]
PEDDER ET AL. 5
2.5 | Dataset-generating mechanisms for
all simulations
All generated datasets contained multiple two-arm studies
that together formed a closed loop of three treatments, A
(the network reference treatment), B and C. Four studies
compared each treatment pair (A vs B, B vs C and A vs C),
giving a total of 12 studies. For each study, the aggregate-
level means from each arm were generated at six time-
points (Supplementary Figures and Tables) based on a two-
parameter Emax time-course function (1). The Emax model
was used to generate all datasets as it is a flexible family of
curves, commonly used for modeling time-course in
pharmacometrics and clinical pharmacology, with clearly
interpretable parameters. Since it contains more than one
time-course parameter, it also allows investigation of the
relationship between multiple time-course parameters. We
specify relative treatment effects on both ET50,i,k and Emax,i,
k that adhere to consistency relationships (3).
Values of each parameter used in the simulation are
given in Table 1. Treatment effects for ET50 are given on
the natural logarithmic scale to ensure absolute ET50
values are positive.
In preliminary work, we investigated varying the SE
for study means. We found that results from datasets gen-
erated with higher SEs (lower precision) typically followed
a similar pattern to results from datasets generated with
lower SEs (higher precision), but with more uncertainty in
estimates and higher Markov chain Monte Carlo (MCMC)
convergence failure. We calculated SEs based on a coeffi-
cient of variation, SEi,k,mθi,k,m × 100
 
=0.5%. This was slightly
lower than the coefficient of variation found in the pain
relief in osteoarthritis dataset10 (median: 3.14%; range:
1.32%-8.55% across all observations), yet we wanted to
obtain a low level of MCMC convergence failure in order
to be able to evaluate performance measures.
2.5.1 | Study I
For Study I observations were generated from an Emax time-
course function with common effects on both Emax and
ET50 parameters and no residual correlation between
time points. In order to investigate how the presence of
observed data at different follow-up times may affect esti-
mation of a time-course MBNMA model, observations
were removed from studies in different comparisons in
the following patterns to generate different datasets.
These patterns were designed to illustrate cases when we
have limited or no direct evidence, but some indirect evi-
dence on different time-course parameters. We have
referred to the patterns within figures pictorially using a
grid system (Figure 1).
Based on an expected empirical SE of 0.5 for dEmax and
0.05 for dET50 , we calculated that 5000 simulations would
result in a Monte Carlo SE (MCSE) of 0.005 for dEmax and
0.0005 for dET50 , which was more than sufficient for our
investigations.
2.5.2 | Study II
In order to investigate the impact of fitting different time-
course MBNMA models and using different strategies to
select between them, datasets were generated using dif-
ferent combinations of the following characteristics to
produce 15 different data-generating models:
• Different covariance structures
 Compound symmetry (CS)
 Autoregressive (AR1)
TABLE 1 Parameters and their values used in all datasets and
the interpretation of those parameter values
Parameter value Interpretation
dEmaxA,B = −5 The maximum effect for
treatment B is 5 points less than
for treatment A
dEmaxA,C = −15 The maximum effect for
treatment C is 15 points less
than for treatment A
dET50A,B = −0:2 The effect of treatment B is to
reduce the time at which 50% of
the maximum effect is observed
by exp(−0.2) = 0.819 when
compared with treatment A
dET50A,C = −0:5 The effect of treatment C is to
reduce the time at which 50% of
the maximum effect is observed
by exp(−0.5) = 0.607 when
compared with treatment A
μEmax,i N −40,1ð Þ The mean maximum response for
the treatment in arm 1 of each
study is normally distributed
around a mean of −40 and
variance of 1.
μET50,i N log 2:5ð Þ,0:0001ð Þ The mean time at which 50% of the
maximum response for the
treatment in arm 1 of each study
is observed is normally distributed
around a mean of log(2.5) = 0.916
and variance of 0.0001.
Note: Under the consistency assumption, dEmaxB,C = dEmaxA,C−
dEmaxA,B = −10 and dET50B,C = dET50A,C−dET50A,B = −0:3 , which
implies that for treatment C the time at which 50% of the maximum
effect is observed is reduced by exp(−0.3) = 0.741 when compared
with treatment B.
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• Different degrees of correlation between observations.
As the interpretation of correlation coefficients
changes depending on the covariance structure, we
selected values for ρAR1 that had a mean correlation
coefficient for all time points equal to ρCS.
 High correlation (ρCS = 0.7, ρAR1 = 0.924)
 Moderate correlation (ρCS = 0.2, ρAR1 = 0.699)
 No correlation
• Between-study SD (τ)
 Common treatment effects on Emax and ET50
(τEmax = 0 and τET50 = 0)
 Random treatment effects on Emax with moderate
heterogeneity (τEmax = 1 ) and common treatment
effects on ET50 (τET50 = 0)
 Random treatment effects on Emax with high hetero-
geneity (τEmax = 5) and common treatment effects on
ET50 (τET50 = 0)
These models were then applied to four different sets
of included studies, selected based on results from Study
I (Figure 1).
In total this produced 60 different datasets for Study II.
Given that there were many more datasets gener-
ated for Study II than for Study I, we examined using
fewer simulations to decrease computational time.
Based on an expected empirical SE of 0.5 for dEmax and
0.05 for dET50 , 742 simulations would be expected to
result in a Monte Carlo SE (MCSE) of 0.013 for dEmax
and 0.0013 for dET50 , which was sufficient for our
investigations.
2.6 | Analysis for all simulations
The following estimands were used in both studies:
• The relative treatment effects of treatments B and C
compared to the network reference treatment (A) for
the different time-course parameters for Emax models
(ET50 and Emax): dEmaxA,B, dEmaxA,C, dET50A,B and dET50A,C
• The predicted mean responses at 2, 6 and 12 weeks fol-













C,12), were derived by applying the estimated
relative effects to the following assumed absolute
parameter values on reference treatment A10,14: E0
=100, Emax = − 40 and ET50 = log(2.5). This allowed
for comparison of performance measures between
models with different time-course functions.
The posterior median was used as the central mea-
sure for each parameter, and the posterior SD as an indi-
cator of precision.
2.6.1 | Study I
For Study I, the focus was on identifying how the estima-
tion of time-course parameters was affected by the
removal of different time points, given correct model
specification. We therefore used the same model for anal-
ysis as was used to generate the data.
2.6.2 | Study II
For Study II, 15 different models were used for analysis
(Table 2). The following model fit statistics were calcu-
lated for each analysis model, and are described in more
detail in Supplementary Methodology:
• The posterior mean of the residual deviance (Dres)
• The posterior mean of the deviance (D)
 The effective number of parameters, calculated
using either the plug-in method (pD),
15 or an
approximation to the effective number of parame-
ters (pv).
16
• The Deviance Information Criterion (DIC), calculated
using two different approaches to compare their per-
formance for model selection:
DICD = Dres + pD
DICv = D+ pv
2.7 | Performance measures for all
simulations
For each parameter of interest, we calculated three mea-
sures of performance. Bias was calculated to establish how
reliably the posterior median targets the true parameter
value. It can be expressed either as an absolute value or as
a % of the true parameter value, thereby facilitating com-
parisons between parameters on different scales. Model SE
is the mean of the posterior SDs for a parameter over all
the simulations and was calculated to reflect the precision
of the model. % error in model SE vs empirical SE (subse-
quently referred to as “% error in SE”) was calculated
to identify how reliably the posterior SD targets the long-
run SD of the posterior median and it is therefore a mea-
sure of how reliably a model captures the “true” degree of
precision in the data. Positive values reflect an underesti-
mation of precision, whilst negative values reflect an
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overestimation of precision. For details of their calcula-
tion, see Supplementary Methodology.
MCMC convergence failure was evaluated as an addi-
tional measure of performance, as this reflects the
identifiability of parameters in the different scenarios.
When presenting the performance measures from
multiple datasets simultaneously, we report the median
and range across the different datasets, as these are
highly skewed and we aim to show the limits of the
results we have found in these datasets.
2.7.1 | Study I
Performance measures were only calculated for datasets
in which >90% of the simulations successfully converged.
Results for datasets with <90% convergence are likely to
suffer from excessive selection bias since results can only
be reported for simulations that converge successfully.
2.7.2 | Study II
Performance measures were estimated for the selected
model across all simulations within a particular dataset,
as evaluated by different model selection strategies, using
both DICD and DICv. To select a model in each simula-
tion, DIC between different analysis models were
compared, excluding those that failed to converge. The
DIC for all converged models were ordered and the
model with the lowest DIC was selected. However, if sev-
eral models were within 3 DIC points from the model
with the lowest DIC, a specific model selection strategy
was used to select between these models (Table S2). We
examined how results differed depending on which of
three different model selection strategies was used:
1. “Best fit”: Choose the model with the best fit (lowest
deviance)
2. “Simplest”: Choose the simplest model that is, the one
with the lowest effective number of parameters (pD or
pv depending on whether DICD or DICv respectively
was being used to compare models)
3. “Staged strategy”: Pedder et al10 proposed a staged
model selection process, where at each stage the sim-
pler model is preferred over a more complex model
from a subsequent stage unless the difference in DIC
to the more complex model is >3. This approach
involves the following stages:
a. Fit common effect models with different time-
course functions
b. Compare random vs common treatment effects
models for the selected time-course function from (a)
c. Compare univariate vs multivariate (with different
correlation structures) likelihoods for the model
selected from (b)
TABLE 2 Different models used for analysis of datasets generated for Study II
Likelihood Time-course λ1, i, k treatment effects λ2, i, k treatment effects
Univariate Emax Common Common
Univariate Emax Random Common
Univariate Emax Common Random
Multivariate (CS) Emax Common Common
Multivariate (CS) Emax Random Common
Multivariate (CS) Emax Common Random
Multivariate (AR1) Emax Common Common
Multivariate (AR1) Emax Random Common
Multivariate (AR1) Emax Common Random
Univariate Exponential Common -
Univariate Exponential Random -
Multivariate (CS) Exponential Common -
Multivariate (CS) Exponential Random -
Multivariate (AR1) Exponential Common -
Multivariate (AR1) Exponential Random -
Note: For Emax time-course, λ1,i,k and λ2,i,k correspond to Emax and ET50 parameters respectively. For exponential time-course
f si,m,λ1,i,kð Þ=E0,i,k + eλ1,i,k × si,m , such that λ1,i,k corresponds to the rate of growth/decay. CS and AR1 indicate compound symmetry and auto-
regressive AR1 covariance structures respectively for models with multivariate likelihoods. The following model characteristics are defined
in equations: Emax time-course function (1), Random treatment effects (2), Common treatment effects (2) (with τ
2 = 0).
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An advantage of the “staged strategy” selection is that
fewer models need to be evaluated.
Performance measures were also calculated sepa-
rately for each analysis model to demonstrate the impor-
tance of model selection and the impact of failing to
properly account for important modeling characteristics
such as heterogeneity or correlation. However, many of
these models are of limited interest since they would
never be selected by any model selection strategy. Results
for these are available in the appendix (Supplementary
Figures - Extended) but are also commented on briefly in
the manuscript.
2.8 | Implementation
Data were simulated in R version 3.5.117 using the 64-bit
Mersenne twister algorithm for random number
generation,18 with input seeds of 15 432, 25 432, 35 432,
45 432, 55 432, 65 432, 75 432 and 85 432 (one for each of
eight different nodes of the cluster computer used for
analysis).
Analysis was carried out in a Bayesian framework
using JAGS19 implemented using a development version
of the MBNMAtime20 package in R (now available on
CRAN). Scripts were multi-threaded to allow simulations
to take place in parallel on 8 nodes of a cluster computer
(Lenovo nx360 m5 compute nodes with two 14 core
2.4 GHz Intel E5-2680 v4 [Broadwell] CPUs and 128 GiB
of RAM), with each of the three MCMC chains of the anal-
ysis being run in parallel on different processors of the
nodes. Different numbers of iterations were used for differ-
ent time-course models depending on their complexity:
• Emax time-course models: 50 000 burn-in iterations;
100 000 monitored iterations
• Exponential time-course models: 30 000 burn-in itera-
tions; 30 000 monitored iterations
Alternative MCMC algorithms can also be used for
Bayesian inference, and it is likely several of these would
result in more rapid convergence. We use Gibbs sampling
here as it is the algorithm used in JAGS,19 the software in
which the MBNMAtime20 package has been developed.
Whilst other MCMC samplers/algorithms, such as Hamil-
tonian Monte Carlo,21 can be more efficient we do not
expect them to result in different numbers of successfully
converged simulations since the number of sampled itera-
tions was large, ensuring that convergence failure arose
due to identifiability (eg, sparse data) rather than sam-
pling issues.
Models were considered to have “failed” to converge
if any of the parameters had ~R>1:2 ,
22 where ~R is the
ratio of the average variance of draws within each
MCMC chain to the variance of the pooled draws across
all chains. Values close to one therefore indicate good
mixing of MCMC chains.
Vague normal prior distributions (N(0, 1000)) were
given to the basic parameters dET50,A,k , dEmax,A,k , dλ, A, k
(where k can take either B or C) and nuisance parameters
μEmax,i, μET50,i and μλ,i. For μET50,i it was necessary to ensure
that they only took positive values so priors for these
were specified on the log-scale. Between-study SDs were
given wide uniform prior distributions (U(0, 100)). In
models with a multivariate likelihood, ρCS and ρAR1 were
given a uniform prior distribution (U(−1, 1)).
3 | RESULTS
3.1 | Study I
3.1.1 | Convergence
A very small proportion of analyzes failed to converge for
the majority of datasets in Study I (<1.46% in Grids 1-4,
6-8, 10, 11-13 & 15-17). However, when both direct evi-
dence for the AvB comparison and indirect evidence aris-
ing from AvC and BvC were limited (Grids 14 & 18),
there was insufficient information to identify the models,
leading to failure to converge in all simulations. When
there was insufficient direct evidence for AvB to identify
parameters this comparison, indirect evidence arising
from AvC and BvC was able to help inform them,
resulting in low convergence failure (3.28% in Grid 5 and
5.66% in Grid 9).
As convergence failure was much greater than 10% in
Grids 14 & 18, performance measures have not been cal-
culated for these datasets as this would introduce selec-
tion bias on estimation of the performance measures.
3.2 | Performance measures
3.2.1 | Bias
Mean bias (reported as a proportion of the true parameter
values) on time-course parameters dEmax,A,B and dET50,A,B
was higher in datasets in which there was insufficient direct
evidence for AvB to independently estimate the time-course
function but where indirect evidence arising from AvC and
BvC was still available (Figure 2A; Grids 5 & 9).
In all other datasets in which time points were
removed, % mean bias on all time-course parameters was
very low (range: −1.78% to 1.79%) in Grids 1-4 & 6-8 (Fig-
ure 2A), even when time points were simultaneously
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removed from studies in two comparisons in the network
(Grids 11-13 & 15-17).
Although mean bias for predicted means followed a very
similar trend to the mean bias for time-course parameters as
time points were removed, mean bias as a % of the true
value was much smaller, and the range of bias in simula-
tions much lower (Supplementary Figures - Extended).
3.2.2 | Model SE vs empirical SE
Model SE increased for parameters relating to the com-
parison from which the time points were removed. When
removing time points from studies comparing treatment
B to treatment A (Grids 2-10), model SE only increased
markedly for dEmax,A,B and dET50,A,B (though there was also
a very slight increase for dEmax,A,C and dET50,A,C ) (Figures
S3 and S4). However, for dEmax,A,B , there was also a very
clear decrease in model SE when direct information on
the time-course for AvB was very limited (Grids 5 & 9),
which increased again when studies comparing AvB were
completely removed (Grid 10).
As with mean bias the effect on model SE of remov-
ing time points for predicted means followed a very simi-
lar trend to time-course treatment effects (Supplementary
Figures - Extended).
% error in SE was generally low for all parameters in all
datasets and remained stable regardless of which time
points were removed from particular parts of the time-
course curve in studies for any particular comparison
FIGURE 2 Mean bias as a % of
true parameter value A, and % error
in SE B, for treatment effect
parameters in datasets in Study I
with different patterns of study/time
point removal (see Figure 1). Error
bars extend symmetrically beyond y-
axis limits for some points and are
not visible for others where 95% CrIs
are too narrow [Colour figure can be
viewed at wileyonlinelibrary.com]
10 PEDDER ET AL.
(range: −2.59% to 2.60%) (Figure 2B). Parameters that
started with a lower error relative to other parameters con-
tinued to have a relatively lower error as time points were
removed. This indicated that so long as parameters could be
identified and convergence was successful, the models reli-
ably captured the true degree of precision in the data.
3.3 | Study II
3.3.1 | Convergence
Failure to converge was low in most datasets, though fail-
ing to correctly model heterogeneity on Emax in datasets
in which heterogeneity was present led to an increased %
of simulations that failed to converge when there was
limited direct evidence on one comparison (Figure S5;
Grids 5 & 9). Correctly modeling this heterogeneity
reduced the % of simulations that failed to converge to
almost 0%. A smaller, yet opposite, effect was found in
datasets in which correlation was present, where model-
ing correlation in the MBNMA model led to slightly
higher failure to converge in Grids 5 & 9.
3.3.2 | Model selection
Where applicable, model selection methods frequently
identified the different structural components of the true
model from which the data were generated (Figure 3). In
datasets with no residual correlation between time
points, DICv model selection methods typically identified
the true model in 91.8% (range: 7.80% to 100%) of simula-
tions across all methods, compared with 58.3% (range:
4.44% to 100%) for DICD. This difference was particularly
evident in datasets in which time points/studies had been
removed (Supplementary Figures - Extended). However,
in datasets generated with moderate heterogeneity the
results were more similar, and DICD identified the true
model in a higher % of simulations (median: 61.0%) than
DICv (median: 47.7).
When using DICv as a model selection statistic, “sim-
plest” and “staged strategy” selection methods produced very
similar results. Across all datasets, they selected the same
analysis model in 94.8% of simulations. These two methods
often failed to select a model that accounted for heterogene-
ity correctly, preferring models with common treatment
effects (Figure 3, in addition to figures in Supplementary Fig-
ures - Extended). For datasets generated with moderate het-
erogeneity, “simplest” and “staged strategy” methods with
DICv correctly selected random treatment effects on Emax in
59.3% of simulations, compared to 85.6% for the “fit”
method, which resulted in lower precision of estimates.
As mentioned in the Supplementary Methodology,
DICD cannot be calculated for multivariate models which
account for correlation between observations. However,
DICv was able to select the same covariance structure as
was used to generate the data in 77.1% of simulations
(Figure 3, in addition to figures in Supplementary Figures
- Extended), suggesting that this is a reliable statistic for
comparing multivariate models in many scenarios, pro-
vided the correlation is of sufficient strength. However,
in datasets generated with moderate CS covariance, DICv
only selected a multivariate model with the correct
covariance structure in 6.07% of simulations.
Selected models in all datasets and model selection
methods had an Emax time-course function. An exponen-
tial time-course was never selected, and results of perfor-
mance measures for these models are therefore not
shown.
FIGURE 3 % of simulations in
which different model selection
strategies identified the “true”
structural components (time-course
function, treatment effects,
covariance structure) of the model
from which the data were generated
with varying degrees of
heterogeneity and correlation.
Results are shown for DICD and
DICv used as model selection
statistics, with models selected based
on best fit, simplest, or staged
selection strategies. Results are
shown for datasets in which all
studies/time points are included
(Grid 1) [Colour figure can be
viewed at wileyonlinelibrary.com]
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3.3.3 | Performance measures
We only present performance measures for the final
model from each simulation here as selected by the
“staged strategy” model selection method using DICv,
since it identified an appropriate model reliably and was
computationally the most efficient. Across all datasets it
required fewer models to be fitted when compared with
either “best fit” or “simplest” selection methods. In
datasets with no heterogeneity or residual correlation
between time points, as many as eight fewer models
needed to be run for each simulation. Results for other
model selection methods are not shown here but are
available on request.
FIGURE 4 Mean bias as a % of true parameter value A, and % error in SE B, for time-course parameters from MBNMA models selected
as the best using DICv “staged strategy” model selection in Study II. Results are presented by dataset with different heterogeneity, correlation
specification and patterns of study/time point removal (see Figure 1). Error bars extend symmetrically beyond y-axis limits for some points
and are not visible for others where 95% CrIs are too narrow [Colour figure can be viewed at wileyonlinelibrary.com]
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Bias
Mean bias as a % of true parameter values on time-
course parameters was low (range: −0.8% to 0.9%) in
datasets with none or moderate heterogeneity and
information at all time points (Figure 4A; Grid 1). This
increased (range: −0.3% to 5.6%) in datasets with high
heterogeneity (Grid 1). Removing studies/time points
from the observed data led to increased % mean bias
(Grids 5, 9 & 10). As in Study I, % mean bias was typi-
cally higher when there was limited direct evidence
for AvB (Grid 9) than when these studies were
removed, and time-course parameters were only
informed by indirect evidence arising from AvC and
BvC (Grid 10).
FIGURE 5 Mean bias as a % of true parameter value A, and % error in SE B, for predicted mean responses on treatments B and C, at 2,
6 and 12 weeks follow-up from MBNMA models selected as the best using DICv “staged strategy” model selection in Study II. Results are
presented by dataset with different heterogeneity, correlation specification and patterns of study/time point removal (see Figure 1). Error
bars extend symmetrically beyond y-axis limits for some points and are not visible for others where 95% CrIs are too narrow [Colour figure
can be viewed at wileyonlinelibrary.com]
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FIGURE 6 Mean bias as a % of true parameter value A, and % error in SE B, for predicted mean responses on treatments B and C, at 2, 6
and 12 weeks follow-up from different MBNMA models in datasets in which all studies/time points are present. Results are presented by
dataset with different heterogeneity and correlation specification. Within the MBNMA analysis model name, the first “ce” or “re” represents
common or random treatment effects respectively on Emax and the second represents common or random treatment effects on ET50. For
exponential there is only a single time-course parameter and “ce” or “re” represents common or random treatment effects on that
parameter. AR1 or CS indicate that correlation has been accounted for using the respective covariance matrix structure. The true model from
which the data were generated in each panel is indicated by the vertical black dashed line. High heterogeneity datasets have been excluded
from results as they have high % convergence failure and so would exhibit extreme selection bias. Error bars extend symmetrically beyond y-
axis limits for some points and are not visible for others where 95% CrIs are too narrow [Colour figure can be viewed at
wileyonlinelibrary.com]
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Results from datasets with moderate heterogeneity
showed a very similar pattern of bias to those from
datasets with no heterogeneity. The exception to this was
in datasets with high correlation, in which case % mean
bias was slightly attenuated in datasets with moderate
heterogeneity compared to those with no heterogeneity
in Grids 5 & 9.
The impact of heterogeneity, correlation, and the
removal of studies or time points on bias followed a very
similar pattern for predicted means as for time-course
parameters. However, as in Study I % mean bias was sub-
stantially lower (range in % mean bias: −0.01% to 0.44%
in Grid 1 datasets), and the 95%CrIs substantially
narrower, implying less variability in bias (Figure 5A).
Model SE vs empirical SE
For time-course parameters and predicted means, model
SE was higher in datasets with heterogeneity, and
increased as time points/studies were removed from the
datasets (Supplementary Figures - Extended).
% error in SE followed very similar patterns in all
datasets for time-course parameters and predicted means.







B,12) followed an almost identical pattern to dEmax,A,B







C,12 ) followed an almost identical pattern to
dEmax,A,C , highlighting the importance of Emax parameter
estimation on % error in SE for making predictions.
% error in SE was always positive except in datasets
generated with AR1 covariance structure when limited
direct evidence on AvB was available (Grids 5 & 9). As
the model SE targets the empirical SE, this suggests that
these models are more likely in general to “underesti-
mate” the precision, leading to more conservative 95%
CrIs for parameters of interest. Within datasets generated
with AR1 covariance structure in Grids 5 & 9 the % error
in SE was more extreme for the time-course parameter
for which there was more information available, and this
had a corresponding effect on predicted means in the
case of Emax parameters.
As would be expected given previous results, reduced
information in the generated data (either due to removal
of time points/studies for a given comparison or higher
heterogeneity/correlation) led to more extreme % error in
SE. However, unlike results for bias, removing studies for
a comparison (Grid 10) frequently resulted in poorer per-
formance in terms of % error in SE than when removing
time points (Grids 5 and 9).
Impact of ignoring heterogeneity/correlation
Failure to properly model heterogeneity or correlation
that was present in the generated data did not lead to
substantial bias in either the time-course parameters or
predicted means, unless an exponential time-course func-
tion was used (Figure 6A). However, there was a signifi-
cant impact of ignoring either heterogeneity or
correlation on % error in SE (Figure 6B).
In datasets generated with no heterogeneity, using a
model for analysis with the same covariance structure as
that used to generate the data led to the % error in SE
being very close to zero, even when time points or studies
were removed from the data. However, failing either to
model the correlation, or to use the correct covariance
structure, led to substantial % error in SE, particularly
when the correlation was high. In datasets in which there
was heterogeneity, the impact on % error in SE of failing
to account correlation between observations appeared
less than in datasets with no heterogeneity.
Failing to account for heterogeneity in the analysis
when it was present in the generated data also had a con-
siderable impact on % error in SE, even when the degree
of true heterogeneity was only moderate. Using a com-
mon treatment effects model when a random effects
model that accounted for heterogeneity on Emax was
more appropriate led to negative error, a substantial
“overestimation” of precision that led to 95% CrIs appe-
aring tighter than they should be given the variability in
the data. This effect was also exacerbated by the impact
of removing studies/time points from the data (Supple-
mentary Figures - Extended).
4 | DISCUSSION
This paper describes two studies evaluating the perfor-
mance of time-course MBNMA in a series of simulated
datasets of aggregate RCT responses. Study I investigated
how MBNMA model parameters are affected by the
quantity and location of observed time points within the
dataset, whilst Study II investigated how reliably an
appropriate model can be identified and how robustly the
outputs can be estimated from the selected model.
4.1 | Study I
Study I illustrates that it is important to consider the
quantity and location of observed follow-up times within
studies in an MBNMA. We found that when there was
insufficient direct evidence to be able to independently
estimate the Emax time-course function parameters for a
particular treatment comparison, it resulted in greater
bias and convergence failure in the corresponding time-
course parameter estimates. This was due to the difficul-
ties of reconciling the two time-course models - a pre-
cisely estimated indirect model and a very imprecisely
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estimated direct one, even though the data were simu-
lated under the assumption of consistency between direct
and indirect evidence. However, bias remained low in all
scenarios for predicted means. If the objective of the syn-
thesis is to predict the results of a potential future study
or to estimate clinical results to be used in a cost-effec-
tiveness analysis, the predicted responses are most likely
to be of interest, and bias in the time-course parameters
may not be of concern. On the other hand, for consulta-
tions with clinicians in which relative effects may be of
greater interest, time-course parameters may be the focus
of the analysis and potential bias of more concern.
The implications of our findings are that whilst we
can reliably make use of indirect evidence to inform rela-
tive effects between treatments for which there is no
direct evidence available, caution may have to be used if
there is direct evidence available for a particular compari-
son that is only provided by studies that include limited
time-course information.
In such a scenario, the choice of modeling approach
should again depend on the objective of the analysis. If
modeling the time-course is of particular importance (eg,
in drug development) and there is a subset of focal treat-
ments on which there is sufficient data, then one option
may be to exclude treatments with limited data that are
less crucial to decision-making. Alternatively, if estimat-
ing efficacy of all treatments simultaneously at a single
time point is a priority then, provided data are available
at that time point, a simple NMA should be a preferred
approach as no assumption regarding the time-course
relationship is required (although making this assump-
tion can also provide additional precision even if only a
single time point is of interest). However, there may be
no time points at which data are available on all treat-
ments, and we advise against “lumping” together data at
different follow-up times for the purposes of synthesis, as
this can introduce heterogeneity.23
A final option would be to model the time-course
using MBNMA but to allow for sharing of information
on a particular time-course parameter across treatments
in the network, which may improve parameter
identifiability and allow models to converge. In a time-
course MBNMA of pain relief in osteoarthritis,10 there
was only direct evidence available at two observations for
two treatments in the network, and for many other treat-
ments there was limited information at earlier time
points, meaning that there was insufficient evidence to
inform both parameters of the Emax time-course model
that was used. Information on the ET50 parameter was
therefore shared across different treatments in the net-
work to allow its estimation. Whilst this allowed for esti-
mation of an Emax function, it is likely to have induced
some bias in relative effects for these treatments.
The Emax relationship has previously been investi-
gated in a dose-response simulation study.24 In contrast
to our results, Dutta et al24 found that even with a wide
spread of data over the Emax relationship, bias on Emax
and EC50 (analogous to ET50 for dose-response relation-
ships) was high (>15%), and it increased as the range of
observations decreased. Despite this, Dutta et al24 found
similarly to our study that predicted values from the
models were accurate, provided predictions were within
the observed concentration range. The lower bias on Emax
parameters found in MBNMA may be due to the added
benefit of using indirect evidence and, were this evidence
also to be removed from the network, convergence issues
would likely be a problem before the extent of bias found
by Dutta et al24 was reached.
Understanding how the quantity of observed data and
the follow-up times at which data are reported may affect
estimation of time-course treatment effects also depends
on which time-course parameter(s) are of interest. For an
Emax relationship the maximum achievable response rela-
tive to competitor treatments (dEmax,c,k ) might be consid-
ered to be the desired “target,” in which case studies
(contributing either direct or indirect evidence) that can
provide most information to dEmax,c,k will report outcomes
at later follow-up times. On the other hand, for condi-
tions in which speed of onset relative to other treatments
might be more of an issue, such as migraine or illnesses
in which current treatments take a long time to act (eg,
psychiatric), precision and reliability in estimating
dET50,c,k may be more important. In these cases, studies
that report time points closer to ET50 are invaluable.
When considering the impact of reported follow-up times
in a MBNMA, it may also be useful to consider the design
of the included studies. With regards to an Emax time-
course function, earlier phase studies are typically shorter
in duration but can often include more observations.
Whether Emax is reached in these shorter studies will
depend on the onset of action of the drug and type of dis-
ease being investigated. For example, pain drugs typically
have a quick onset of action and it is likely Emax can be
well estimated in a short duration study but conversely,
for drugs aimed at losing weight, Emax might not be well
characterized in these early patient trials.
Within pharmacometrics, optimal experimental
design theory seeks to identify the most important mea-
surements required to reliably characterize a dose-
response or time-course function.25 Whilst these
approaches are used when designing a study and may
inform the choice of follow-up times used in the study
analysis, it may be possible that the number of follow-up
times collected within the study are not the same as those
reported in the aggregate data, which greatly reduces
their applicability in MBNMA. We urge researchers not
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only to use such methods when designing a study, but
also to report aggregate results at all recorded time
points, as well as the correlations across these time
points, to facilitate estimation of all time-course parame-
ters in MBNMA.
4.2 | Study II
Study II makes contributions to two main areas. It firstly
demonstrates the reliability of our “staged strategy” model
selection method in identifying an appropriate time-course
MBNMA model. This method correctly selected the model
used to generate the data in a high proportion of simula-
tions and was often able to reliably identify the time-course
function, heterogeneity and covariance structure between
time points. Whilst the “simplest” method was also an
effective method for model selection, the benefits of the
“staged strategy” method are that it considerably reduces
the number of potential models that need to be fitted to
identify a final model. Particularly in the case of data with
no heterogeneity or residual correlation between time
points, it negates the need to fit computationally intensive
multivariate models and, in the case of a two-parameter
time-course function, this could lead to up to eight fewer
models being fitted than the “simplest” selection method
without even accounting for the multitude of models that
can be fitted when comparing different time-course func-
tions. The wide range of potential MBNMA models that
can typically be fitted and the computational time required
to run them, particularly when using multi-parameter
time-course functions and multivariate likelihoods, means
that this strategy significantly facilitates the process of iden-
tifying an appropriate time-course MBNMA model.
The evaluation of different model fit statistics in
Study II showed that DICv (calculated using pv
16) per-
forms similarly to DICD (calculated using pD via the plu-
gin method15) for comparing random vs common
treatment effect models, but has the added benefit of
being calculable for multivariate likelihood models,
thereby allowing comparison between univariate and
multivariate models that account for correlation between
time points. Whilst calculation of pD is not possible for
multivariate likelihood models due to the covariance
matrix being estimated from the data, we show that pv
used in DICv is a reliable alternative for comparison of
multivariate likelihood models with different covariance
matrix structures. We therefore would recommend using
DICv with the “staged strategy” selection method for
identifying the appropriate time-course MBNMA model.
This selection method was used for MBNMA of the
pain relief in osteoarthritis dataset,10 for which there had
been a question regarding whether DICv with the “staged
strategy” was able to reliably select between univariate
and multivariate likelihood models. Results from Study II
confirm that this approach is likely to have selected an
appropriate choice of likelihood that will have avoided
substantial bias or increase in % error in SE. Even though
some non-zero correlation was identified when fitting a
multivariate likelihood model in this dataset, it was low,
and the impact on 95% CrIs of relative treatment effects
was negligible, which supported the selection of a univar-
iate likelihood model when using the “staged strategy.”
A second major contribution of Study II is that it
demonstrates the robustness of model predictions and,
though to a slightly lesser extent, estimation of time-
course parameters. As in Study I, we found that very lim-
ited direct evidence led to greater bias on time-course
parameters than in datasets in which only indirect evi-
dence was available. Convergence was an issue in these
datasets, and we suspect that this may have affected a
selective sample of simulations (e.g., those with higher/
lower observed values), which would therefore result in
biased parameter estimates in the remaining converged
simulations.
In particular, Study II highlights the importance of
correctly accounting for heterogeneity and correlation
between observations in MBNMA models, even when the
time-course has been correctly characterized through use
of an appropriate time-course function.
Previous research in meta-analysis has highlighted
the importance of accounting for within-study correla-
tions, such as when analyzing repeated measures,26 and
has also shown that ignoring correlation in model-based
meta-analysis led to inflated residual variance.27 Study II
provides empirical evidence to further support this by
showing that failing to account for substantial correlation
present in the generated data led to increased %
error in SE.
In addition, we demonstrate that the choice of covari-
ance structure can have a considerable impact on % error
in SE. Modeling using a CS covariance structure when
data were generated with an AR1 structure can lead to
considerable % error in SE, and vice versa. It may there-
fore be important to consider a variety of different covari-
ance structure types commonly used to account for
correlation between time points (eg, ARMA, Toeplitz),28
though there may be problems with convergence for
more complex covariance structures if estimation of mul-
tiple correlation coefficients is required.
Model selection methods may also struggle to select
between models with different covariance structures, par-
ticularly if the true correlation is not strong. We found
that in datasets with moderate CS correlation, models
were typically selected that did not account for correla-
tion between time points, and this led to slightly higher
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% error in SE for predicted means and time-course
parameters. It is unclear why this might be the case, why
the same was not found in datasets with AR1 correlation,
and how often this degree of correlation in aggregate data
may occur in practice. One explanation could be due to
the limitations of using DICv for comparison of multivari-
ate models. An alternative approach when comparing
univariate and multivariate models may be to more
closely inspect the correlation parameter (if estimated
from the data) to check for non-zero values.
Failing to account for heterogeneity when it was pre-
sent in the generated data also led to positive % error in
SE, as would be expected when modeling heterogeneous
data using common treatment effects models. Yet in
datasets with heterogeneity on Emax, even when it was
modeled correctly, there was some positive % error in SE
on time-course parameters and predicted means. This
was most likely caused by the upwards bias in τEmax
(Figure S6), which is a common feature when estimating
heterogeneity in meta-analyses.29,30 In this study, our
choice of a conservative U(0, 100) prior distribution for
τEmax may explain the % error in SE identified in datasets
with high heterogeneity.
Heterogeneity parameters are known to be sensitive
to the prior distributions chosen in a Bayesian analysis,
and the use of more realistic distributions such as half-
normal or inverse-gamma priors may reduce bias in their
estimation.30 However, this also highlights a clear benefit
of MBNMA over standard NMA in that by modeling
time-course it reduces heterogeneity that might arise due
to pooling of studies with different follow-up times,
thereby limiting the need to estimate heterogeneity
parameters and the resulting bias from doing so.
4.3 | Limitations
We have only looked at data generated from an Emax rela-
tionship, and one might reasonably ask whether it is fair
to generalize findings from this to other time-course
functions. Whilst we have not approached this in any
detail (primarily due to the potentially vast number of
non-linear relationships), some conclusions are likely to
be more generalisable than others.
When considering the two time-course functions used
for analysis in Study II, the exponential function as we
defined it (Table 2) fitted the data very poorly and was
never selected in any simulation. Whilst this illustrates
clearly that these model selection approaches can reliably
choose between different time-course functions, we
would not expect to encounter this form of an exponen-
tial relationship in a pharmacometric context. We have
since updated the MBNMAtime R package used for
analysis in this study to incorporate a pharmacometric-
specific form of the exponential function which is more
generalisable to longitudinal datasets.31
In terms of the impact of correlation and heterogene-
ity, as well as the performance of model selection
methods, we believe that results from this paper are
generalisable to other time-course functions. However,
when considering the impact of different follow-up times
present in the data, the underlying time-course may lead
to different conclusions.
There are also several factors that we have not consid-
ered here that are likely to be important in time-course
MBNMA which could impact the external validity of the
study. When analyzing longitudinal data, patient drop-out
is often an important consideration. Within the modeling
framework we assume either that there has been no drop-
out, or if there is drop-out then either that it is missing
completely at random, or that any adjustment for dropout
has been accounted for already in the results reported by
included studies. This approach is commonly practiced in
meta-analysis due to only aggregate level data being avail-
able. An alternative approach is to restrict the inclusion
criteria to studies using a specified method of imputation
(eg, Last Observation Carried Forward). Whilst we have
made the simplifying assumption of no drop-out in our
simulations, this has allowed us to focus on the perfor-
mance of the method in the ideal situation with no drop-
out. Methods for investigating different missingness mech-
anisms have been previously described in NMA,32,33 and
these could be extended to MBNMA in future work and
investigated in more detail in simulation.
We have only considered a three-treatment network,
which does not provide information on the effects of
“second order” indirect evidence which may add strength
to improve model estimation.34 More complex network
structures/geometry (ie, the connections between treat-
ments within the network) have been addressed previ-
ously in NMA,35-38 and whilst this is certainly an
important consideration for MBNMA, we expect that
similar approaches and conclusions could be drawn.
Finally, we have not addressed the issue of inconsis-
tency here, the potential discrepancy between direct and
indirect evidence that can arise in networks of evi-
dence.39 Methods for identifying inconsistency in time-
course MBNMA have been proposed,10 but the potential
for testing for inconsistency in network of drug develop-
ment trials may be limited. In early phase studies, active
treatments are all often compared to a common compara-
tor (eg, placebo), and as trials must be internally consis-
tent, differences between trials will manifest as
heterogeneity rather than inconsistency. We hope that
inconsistency in MBNMA is something that can be exam-
ined in future work using simulation, with consideration
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of how model characteristics such as sharing time-course
parameters across treatment comparisons may impact
the ability to detect inconsistency.
5 | CONCLUSIONS
In this paper, we have demonstrated through simulation
that indirect evidence can help estimate time-course
parameters by providing additional information, either
when limited direct evidence is available or in the
absence of head-to-head trials.
We have highlighted the value of a model selection
strategy for identifying an appropriate MBNMA model,
and shown that DIC is a reasonable model selection statis-
tic to use for comparison, even when it is calculated using
pv for the effective number of parameters. It also empha-
sizes the importance of correctly accounting for correlation
between time points through the use of a multivariate like-
lihood with an appropriate covariance structure, and of
modeling any heterogeneity present in the data.
We find that although there are some scenarios in which
time-course parameter estimates may be biased, predicted
responses can still be estimated reliably, which helps indicate
the circumstances in which time-course MBNMA can be
most useful. The true degree of precision is typically well esti-
mated by the models provided that any heterogeneity in the
data has been modeled and that correlation between time
points has been appropriately accounted for.
This work demonstrates the validity of time-course
MBNMA methodology and lends support to the wider
application of MBNMA in evidence synthesis.
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